Skip to main content
Erschienen in: Documenta Ophthalmologica 2/2008

01.09.2008 | Original Research Article

Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy

verfasst von: Ulrika Kjellström, Monica Lövestam-Adrian, Sten Andréasson, Vesna Ponjavic

Erschienen in: Documenta Ophthalmologica | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose In numerous studies vigabatrin medication has been associated with visual field constriction and alterations in the full-field electroretinogram (ff-ERG), but it is not clear whether these changes are reversible or not. The purpose of this study was to examine patients with visual field loss and reduced ff-ERG several years after discontinuing vigabatrin therapy, in order to investigate reversibility. Methods Eight patients with visual field constriction and reduced cone responses measured by 30 Hz flicker ERG were examined with Goldmann perimetry and ff-ERG 4–6 years after discontinuing medication. The results were compared with investigations conducted during medication, 4–6 years previously. Statistical analysis was also used to compare the ff-ERG results of the patients, during treatment and at follow-up, with a group of 70 healthy subjects. Results Visual field constriction remained 4–6 years after discontinuing vigabatrin therapy. The amplitude of the 30 Hz flicker response also remained reduced on follow-up both compared with the results during treatment and with the control group. Moreover, the amplitude of the isolated rod response and the combined rod–cone response were decreased in the patients compared with the control group, during vigabatrin treatment as well as on follow-up. On follow-up, oscillatory potentials (OPs) also were registered, showing reduced amplitudes in patients compared with controls. The within subject comparison showed no significant changes. Conclusion Vigabatrin attributed visual field constriction and reduced ff-ERG responses remain several years after discontinuing vigabatrin therapy, indicating drug-induced permanent retinal damage.
Literatur
1.
Zurück zum Zitat Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie M (2003) Vigabatrin, but not gabapentin or topiramat, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886–892PubMedCrossRef Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie M (2003) Vigabatrin, but not gabapentin or topiramat, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 44:886–892PubMedCrossRef
2.
Zurück zum Zitat Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181 Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181
3.
Zurück zum Zitat Backström JT, Hinke RL, Flicker MR (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695 Backström JT, Hinke RL, Flicker MR (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695
4.
Zurück zum Zitat Blackwell N, Hayllar J, Kelly G (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694 Blackwell N, Hayllar J, Kelly G (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694
5.
Zurück zum Zitat Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694 Harding GA (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1694
6.
Zurück zum Zitat Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1693 Wilson EA, Brodie MJ (1997) Severe persistent visual field constriction associated with vigabatrin (letter). Br Med J 314:1693
7.
Zurück zum Zitat Wong ICK, Mawer GE, Sander JWAS (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695 Wong ICK, Mawer GE, Sander JWAS (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:1694–1695
8.
Zurück zum Zitat Kälviänen R, Nousianen I, Mänyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Reikkinen P (1999) Vigabatrin, a GABAergic antiepileptic drug, cause concentric visual field defects. Neurology 53:922–926 Kälviänen R, Nousianen I, Mänyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Reikkinen P (1999) Vigabatrin, a GABAergic antiepileptic drug, cause concentric visual field defects. Neurology 53:922–926
9.
Zurück zum Zitat Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 53:2082–2087PubMed Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL (1999) Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiological findings. Neurology 53:2082–2087PubMed
10.
Zurück zum Zitat Nicolson A, Leach JP, Chadwick DW, Smith DF (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327–329PubMedCrossRef Nicolson A, Leach JP, Chadwick DW, Smith DF (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327–329PubMedCrossRef
11.
Zurück zum Zitat Ponjavic V, Andréasson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63–72PubMedCrossRef Ponjavic V, Andréasson S (2001) Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthalmol 102:63–72PubMedCrossRef
12.
Zurück zum Zitat Lawden MC, Eke T, Degg C, Harding GFA, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716–722PubMedCrossRef Lawden MC, Eke T, Degg C, Harding GFA, Wild JM (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716–722PubMedCrossRef
13.
Zurück zum Zitat Daneshvar H, Racette MA, Coupland SG, Kertes PJ, Guberman A, Zackon D (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophtalmology 106:1792–1798CrossRef Daneshvar H, Racette MA, Coupland SG, Kertes PJ, Guberman A, Zackon D (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophtalmology 106:1792–1798CrossRef
14.
Zurück zum Zitat Nousiainen I, Mantyjarvi M, Kalviainen R (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:1916–1917PubMed Nousiainen I, Mantyjarvi M, Kalviainen R (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:1916–1917PubMed
15.
Zurück zum Zitat Wild JM, Martinez C, Reinshagen G, Harding GF (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784–1794PubMedCrossRef Wild JM, Martinez C, Reinshagen G, Harding GF (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:1784–1794PubMedCrossRef
16.
Zurück zum Zitat Krauss GL, Johnson MA, Sheth S, Miller NR (2003) A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74:339–343PubMedCrossRef Krauss GL, Johnson MA, Sheth S, Miller NR (2003) A controlled study comparing visual function in patients treated with vigabatrin and tiagabine. J Neurol Neurosurg Psychiatry 74:339–343PubMedCrossRef
17.
Zurück zum Zitat Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M (1998) Electrophysiological evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116:817–819PubMed Ruether K, Pung T, Kellner U, Schmitz B, Hartmann C, Seeliger M (1998) Electrophysiological evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol 116:817–819PubMed
18.
Zurück zum Zitat Graniewski-Wijnands HS, van der Torren K (2002) Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104:189–194PubMedCrossRef Graniewski-Wijnands HS, van der Torren K (2002) Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 104:189–194PubMedCrossRef
19.
Zurück zum Zitat Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B (2002) Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol 249:1066–1071PubMedCrossRef Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B (2002) Is visual field constriction in epilepsy patients treated with vigabatrin reversible?. J Neurol 249:1066–1071PubMedCrossRef
20.
Zurück zum Zitat Newman WD, Tocher K, Acheson JF (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567–571PubMedCrossRef Newman WD, Tocher K, Acheson JF (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567–571PubMedCrossRef
21.
Zurück zum Zitat Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, Van Veelen C (2003) Vigabatrin: longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81:459–465PubMedCrossRef Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, Van Veelen C (2003) Vigabatrin: longterm follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 81:459–465PubMedCrossRef
22.
Zurück zum Zitat Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR (2000) Visual function loss from vigabatrin. Effect of stopping the drug Neurology 55:40–45 Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR (2000) Visual function loss from vigabatrin. Effect of stopping the drug Neurology 55:40–45
23.
Zurück zum Zitat Fledelius HC (2003) Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 81:41–45PubMedCrossRef Fledelius HC (2003) Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 81:41–45PubMedCrossRef
24.
Zurück zum Zitat Krakow K, Polizzi G, Riordan-Eva P, Holder G, Macleod W, Fish D (2000) Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9:287–290PubMedCrossRef Krakow K, Polizzi G, Riordan-Eva P, Holder G, Macleod W, Fish D (2000) Recovery of visual field constriction following discontinuation of vigabatrin. Seizure 9:287–290PubMedCrossRef
25.
Zurück zum Zitat Versino M, Veggiotti P (1999) Reversibility of vigabatrin induced visual-field defect. Lancet 354:486PubMedCrossRef Versino M, Veggiotti P (1999) Reversibility of vigabatrin induced visual-field defect. Lancet 354:486PubMedCrossRef
26.
Zurück zum Zitat Hammond EJ, Rangel RJ, Wilder BJ (1988) Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 61:16–23 Hammond EJ, Rangel RJ, Wilder BJ (1988) Evoked potential monitoring of vigabatrin patients. Br J Clin Pract 61:16–23
27.
Zurück zum Zitat Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, Perucca E (1989) Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 27:61–68 Cosi V, Callieco R, Galimberti CA, Manni R, Tartara A, Mumford J, Perucca E (1989) Effects of vigabatrin on evoked potentials in epileptic patients. Br J Clin Pharmacol 27:61–68
28.
Zurück zum Zitat Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P (1989) Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 27:69–72 Liegeois-Chauvel C, Marquis P, Gisselbrecht D, Pantieri R, Beaumont D, Chauvel P (1989) Effects of long term vigabatrin on somatosensory evoked potentials in epileptic patients. Br J Clin Pharmacol 27:69–72
29.
Zurück zum Zitat Mauguiere F, Chauvel P, Dewailly J, Dousse N (1997) No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy, result of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicentergroup. Epilepsia 38:301–308PubMedCrossRef Mauguiere F, Chauvel P, Dewailly J, Dousse N (1997) No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy, result of a multicenter study of somatosensory and visual evoked potentials. PMS Study Multicentergroup. Epilepsia 38:301–308PubMedCrossRef
30.
Zurück zum Zitat Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin Effect on Inner Retinal Function. Ophthalmology 108:1493–1498PubMedCrossRef Coupland SG, Zackon DH, Leonard BC, Ross TM (2001) Vigabatrin Effect on Inner Retinal Function. Ophthalmology 108:1493–1498PubMedCrossRef
31.
Zurück zum Zitat Westall CA, Nobile R, Morong S, Buncic RJ, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299–309PubMedCrossRef Westall CA, Nobile R, Morong S, Buncic RJ, Logan WJ, Panton CM (2003) Changes in the electroretinogram resulting from discontinuation of vigabatrin in children. Doc Ophthalmol 107:299–309PubMedCrossRef
32.
Zurück zum Zitat Van der Torren K, Graniewski-Wijnands HS, Polak BCP (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181–188PubMedCrossRef Van der Torren K, Graniewski-Wijnands HS, Polak BCP (2002) Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol 104:181–188PubMedCrossRef
33.
Zurück zum Zitat Comaish IF, Gorman C, Brimlow GM, Barber C. Orr GM, Galloway NR (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104:195–2129PubMedCrossRef Comaish IF, Gorman C, Brimlow GM, Barber C. Orr GM, Galloway NR (2002) The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol 104:195–2129PubMedCrossRef
34.
Zurück zum Zitat McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61:1690–1694PubMed McDonagh J, Stephen LJ, Dolan FM, Parks S, Dutton GN, Kelly K, Keating D, Sills GJ, Brodie MJ (2003) Peripheral retinal dysfunction in patients taking vigabatrin. Neurology 61:1690–1694PubMed
35.
Zurück zum Zitat Scaioli V, Franceschetti S, Binelli S, Casazza M, Villani F, Granata T, Balestrini MR, Curzi S, Agazzi P, Avanzini G (2005) Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. Int Congr Ser 1278:41–44CrossRef Scaioli V, Franceschetti S, Binelli S, Casazza M, Villani F, Granata T, Balestrini MR, Curzi S, Agazzi P, Avanzini G (2005) Serial electrophysiological studies of the visual pathway in patients treated with vigabatrin. Int Congr Ser 1278:41–44CrossRef
36.
Zurück zum Zitat Besch D, Kurtenbach A, Appfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schiefer U (2002) Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151–170PubMedCrossRef Besch D, Kurtenbach A, Appfelstedt-Sylla E, Sadowski B, Dennig D, Asenbauer C, Zrenner E, Schiefer U (2002) Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 104:151–170PubMedCrossRef
37.
Zurück zum Zitat Marmor MF, Holder GE, Seelinger MW, Yamamoto S. International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114 Marmor MF, Holder GE, Seelinger MW, Yamamoto S. International Society for Clinical Electrophysiology of Vision (2004) Standard for clinical electroretinography (2004 update). Doc Ophthalmol 108:107–114
38.
Zurück zum Zitat Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminas inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695–705PubMedCrossRef Duboc A, Hanoteau N, Simonutti M, Rudolf G, Nehlig A, Sahel JA, Picaud S (2004) Vigabatrin, the GABA-transaminas inhibitor, damages cone photoreceptors in rats. Ann Neurol 55:695–705PubMedCrossRef
39.
Zurück zum Zitat Frisèn L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466–473PubMedCrossRef Frisèn L, Malmgren K (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466–473PubMedCrossRef
40.
Zurück zum Zitat Buncic RJ, Westall CA, Panton CM, Munn RJ, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary inverse optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935–1942PubMedCrossRef Buncic RJ, Westall CA, Panton CM, Munn RJ, MacKeen LD, Logan WJ (2004) Characteristic retinal atrophy with secondary inverse optic atrophy identifies vigabatrin toxicity in children. Ophthalmology 111:1935–1942PubMedCrossRef
41.
Zurück zum Zitat Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM (2006) Detecting vigabatrin toxicity by imaging the retinal nerve fiber layer. Invest ophthalmol vis sci 47:917–924PubMedCrossRef Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PEM (2006) Detecting vigabatrin toxicity by imaging the retinal nerve fiber layer. Invest ophthalmol vis sci 47:917–924PubMedCrossRef
42.
Zurück zum Zitat Rebolleda G, Garcia Pérez JL, Munoz Negrete FJ (2005) Vigabatrin toxicity in children (letter). Ophthalmology 112:1322–1323PubMedCrossRef Rebolleda G, Garcia Pérez JL, Munoz Negrete FJ (2005) Vigabatrin toxicity in children (letter). Ophthalmology 112:1322–1323PubMedCrossRef
Metadaten
Titel
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy
verfasst von
Ulrika Kjellström
Monica Lövestam-Adrian
Sten Andréasson
Vesna Ponjavic
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Documenta Ophthalmologica / Ausgabe 2/2008
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-007-9108-3

Weitere Artikel der Ausgabe 2/2008

Documenta Ophthalmologica 2/2008 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.